Instil Bio, Inc. (TIL) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.46
↓-54% vs avg
5yr avg: 1.02
30Y Low0.2·High3.3
ROE
↓
-50.4%
-11% vs avg
5yr avg: -45.3%
30Y Low-80%·High-25%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TIL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Instil Bio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $54M | $73M | $124M | $50M | $82M | $1.8B | — | — |
| Enterprise Value | $132M | $152M | $202M | $126M | $118M | $1.8B | — | — |
| P/E Ratio → | -0.74 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.46 | 0.64 | 0.73 | 0.22 | 0.22 | 3.27 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TIL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
TIL Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -50.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 100.0% | — |
| Operating Margin | — | — | — | — | — | — | -24379.7% | — |
| Net Profit Margin | — | — | — | — | — | — | -27346.4% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -50.4% | -50.4% | -37.5% | -53.0% | -48.6% | -37.0% | -25.1% | -80.1% |
| ROA | -30.6% | -30.6% | -25.2% | -38.6% | -40.9% | -33.8% | -23.0% | -68.1% |
| ROIC | -18.0% | -18.0% | -20.0% | -34.0% | -33.7% | -41.1% | -101.3% | — |
| ROCE | -23.3% | -23.3% | -25.8% | -41.6% | -40.5% | -35.6% | -21.4% | -81.7% |
TIL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $79M ($85M total debt minus $7M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.75 | 0.75 | 0.51 | 0.38 | 0.22 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.69 | 0.46 | 0.34 | 0.10 | -0.07 | -0.83 | -1.10 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -9.08 | -9.08 | -7.36 | -29.16 | -118.62 | — | — | — |
TIL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Instil Bio, Inc.'s current ratio of 39.53x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 15.22x to 39.53x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 39.53 | 39.53 | 15.76 | 15.22 | 8.22 | 11.22 | 18.53 | 6.54 |
| Quick Ratio | 39.53 | 39.53 | 15.76 | 15.22 | 8.22 | 11.22 | 18.53 | 6.54 |
| Cash Ratio | 15.72 | 15.72 | 14.35 | 14.24 | 7.96 | 10.98 | 18.20 | 6.26 |
| Asset Turnover | — | — | — | — | — | — | 0.00 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
TIL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Instil Bio, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $7M | $7M | $7M | $6M | $5M | $6M | $6M |
Peer Comparison
Compare TIL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TILYou | $54M | -0.7 | — | — | — | — | -50.4% | -18.0% | — |
 IOVA | $1B | -3.7 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 ADCT | $134M | -0.9 | — | — | 90.6% | -133.2% | — | — | — |
 FATE | $240M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 TGTX | $8B | 17.9 | 62.8 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 CRIS | $82M | -0.7 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 ALNY | $38B | 121.4 | 67.0 | 81.1 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 RCUS | $2B | -7.2 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in TIL 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in TIL be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs TIL Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationTIL vs IOVA — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Iovance Biotherapeutics, Inc..
Compare NowTIL — Frequently Asked Questions
Quick answers to the most common questions about buying TIL stock.
What is Instil Bio, Inc.'s P/E ratio?
Instil Bio, Inc.'s current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
What is Instil Bio, Inc.'s ROE?
Instil Bio, Inc.'s return on equity (ROE) is -50.4%. The historical average is -47.4%.
Is TIL stock overvalued?
Based on historical data, Instil Bio, Inc. is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.